Study: Cervarix could cut need for cancer screenings

Two studies published in the journal Lancet Oncology found GlaxoSmithKline's HPV vaccine is so effective that health authorities could eventually consider cutting the recommendation for regular HPV screenings to a one-time test in a woman's mid- to late-twenties. The U.S. and Finnish researchers also found Cervarix protects against several other HPV-types not primarily targeted by the vaccine.

Finland was one of the first countries to support a nationwide HPV vaccination campaign in 2007. Vaccination rates there are high enough that health officials could save money by stopping the now-unnecessary cancer screenings, explains the University of Tampere's Matti Lehtinen, who worked on the studies. The CDC currently recommends women ages 11 to 26 get either Cervarix or Merck's Gardasil, but U.S. vaccination rates are lagging due to concerns about safety and the cost of the vaccines.

"Provided that organized vaccination programs achieve high coverage in early adolescents before sexual debut, HPV vaccination has the potential to substantially reduce the incidence of cervical cancer, probably allowing the modification of screening programs," Lehtinen told Reuters.

- read the article for more

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.